CureMetrix® cmTriage™ helps to triage and prioritize mammography workflow for radiologists
CureMetrix®, a healthcare technology company that develops computer-aided detection (CAD) software based on artificial intelligence (AI), announced today that it has received clearance from the U.S. Food and Drug Administration to market its product cmTriage™.
“Early and accurate detection in breast cancer is key in improving cancer survival rates worldwide through the development of next-generation medical image analysis solutions. With 40 million mammograms a year in the U.S., only five cancers per 1,000 are being found at
“Our ability to bring cmTriage to the medical community is a major milestone in our mission to deliver CAD that Works® to support the radiologist and the patients they serve,” said Kevin Harris, CEO and Board Director for CureMetrix.
Said Lisa Watanabe, M.D., Chief Medical Officer at CureMetrix and Clinical Associate Professor at University of Southern California, “Our goal is to provide radiologists with analytic tools to enhance diagnosis in breast cancer screening and augment treatment decisions.
“On average, early signs of breast cancer may be missed up to 50% of the time on mammograms. Analysis of mammograms with cmTriage has the potential to help radiologists focus on the suspicious cases and increase their productivity. This will allow for more time to engage with our patients and the healthcare team.
“Providing radiologists with the most advanced technology and tools like
Delivering CAD that Works®, CureMetrix is committed to the advancement of technology that improves cancer survival rates worldwide. With research that leverages artificial intelligence (AI) and deep learning to develop the next generation of medical image analysis, CureMetrix delivers technology that radiologists, healthcare systems and patients can confidently rely on. For more information visit www.curemetrix.com. For FDA clearance details, please visit, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K183285